Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | TP53 |
Variant | R213fs |
Impact List | frameshift |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | TP53 R213fs results in a change in the amino acid sequence of the Tp53 protein beginning at aa 213 of 393, likely resulting in premature truncation of the functional protein (UniProt.org). R213fs has not been biochemically characterized however, due to the effects of truncation mutations downstream of R213 (PMID: 31081129, PMID: 34045312), is predicted to lead to a loss of Tp53 protein function. |
Associated Drug Resistance | |
Category Variants Paths |
TP53 mutant TP53 exon6 TP53 R213fs TP53 mutant TP53 inact mut TP53 R213fs |
Transcript | NM_000546.6 |
gDNA | chr17:g.(7674894_7674895) |
cDNA | c.(637_636) |
Protein | p.R213fs |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
NM_001407268.1 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_001126112 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_001126113 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_001126112.2 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_001126114.2 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_000546.5 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_000546.6 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_001126113.2 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_001126114 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_001407270.1 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_001407262.1 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_000546 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_001126113.3 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_001126112.3 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_001407264.1 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_001126114.3 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
NM_001407266.1 | chr17:g.(7674894_7674895) | c.(637_636) | p.R213fs | RefSeq | GRCh38/hg38 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|